Company / Cash & Equivalents
LeMaitre Vascular Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$28.2M
FY2025
5-year range
$13.9M / $28.2M
FY2021-FY2025
Trend
+10.3%
vs FY2024
Sector context
#143 of 148
Health Care
What the data says
Among 148 Health Care companies, LeMaitre Vascular is in the bottom 3% for cash & equivalents. Cash & Equivalents has increased for 4 consecutive years, from $14M in FY2021 to $28M in FY2025.
Based on SEC 10-K filings.
$28M in FY2025 with a 5-year CAGR of +1.1%.
Improved from $24M to $28M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +1.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 148This company $28.2M Sector average $1.2B
▼
-97.6% below sector average
Key checks
Key Insights
- LeMaitre Vascular's cash & equivalents has grown for 4 consecutive years.
- 5-year CAGR of +1.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 10.3% year-over-year.
- Ranks #143 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.2M | +10.3% |
| FY2024 | $25.6M | +5.5% |
| FY2023 | $24.3M | +26.8% |
| FY2022 | $19.1M | +38.1% |
| FY2021 | $13.9M | -48.2% |
| FY2020 | $26.8M | +1.7% |
| FY2019 | $26.3M | +8.4% |
| FY2018 | $24.3M | -11.5% |
| FY2017 | $27.5M | +13.0% |
| FY2016 | $24.3M | +65.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026